Tatjana Kolevska

Hematology Oncology | Hematology | Oncology
975 Sereno Drive
Med Offices 2nd Fl Dept #210
Vallejo, CA 94589

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications

Timeliness, Coordination, Clarity, and Kindness: Patients' Interpretations of Provider Actions as Indicators of Quality Cancer Care.

Timeliness, Coordination, Clarity, and Kindness: Patients' Interpretations of Provider Actions as Indicators of Quality Cancer Care.

Journal: The Permanente journal
Published: August 27, 2026

Response to Yu, Wang, and Ge.

Response to Yu, Wang, and Ge.

Journal: Journal of the National Cancer Institute
Published: April 19, 2026

Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer.

Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer.

Journal: JCO oncology practice
Published: December 11, 2025

The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancer.

The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancer.

Journal: Cancer
Published: September 04, 2025

Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer.

Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer.

Journal: Journal of the National Cancer Institute
Published: August 06, 2025

Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer.

Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer.

Journal: Cancer
Published: July 23, 2025

Evaluation of methods to identify chemotherapy-related hematologic toxicities in real-world settings.

Evaluation of methods to identify chemotherapy-related hematologic toxicities in real-world settings.

Journal: International journal of cancer
Published: July 21, 2025

NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.

NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.

Journal: Cancer chemotherapy and pharmacology
Published: May 14, 2025

Patient characteristics associated with conventional schedule vs. dose dense chemotherapy in women with stage I-IIIA breast cancer.

Patient characteristics associated with conventional schedule vs. dose dense chemotherapy in women with stage I-IIIA breast cancer.

Journal: Breast cancer research and treatment
Published: May 02, 2025

Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer.

Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer.

Journal: NPJ breast cancer
Published: April 30, 2025

Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study.

Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study.

Journal: JCO clinical cancer informatics
Published: February 14, 2025

Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer.

Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer.

Journal: Journal of the National Cancer Institute
Published: December 05, 2024
Showing 1-12 of 48

Last Updated: 09/26/2026